STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with significant upside potential, a bullish technical setup, and promising catalysts in its pipeline. Despite the lack of recent news and congress trading data, the company's advanced ADC platform and upcoming clinical milestones make it a compelling long-term investment.
The technical indicators for STRO are bullish. The MACD is positively expanding above 0, RSI is neutral at 60.208, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 30.486 and 32.154, while support levels are at 27.787 and 25.087.
Strong analyst ratings with multiple Buy and Outperform ratings and price targets ranging from $41 to $
Promising ADC platform with potential blockbuster opportunities in solid tumors.
Upcoming clinical milestones, including mid-2026 data for STRO-004 and STRO-006, which could validate the platform.
$10M milestone from Astellas collaboration, highlighting the company's expanding partnerships.
Lack of recent news or congress trading data to further validate sentiment.
No immediate AI Stock Picker or SwingMax trading signals.
No financial data available for the latest quarter. However, analysts highlight a solid cash position of $212M, which supports ongoing clinical progress.
Analysts are overwhelmingly positive on STRO, with multiple firms initiating or upgrading coverage to Buy or Outperform. Price targets range from $41 to $60, with analysts citing the company's ADC platform, clinical progress, and upcoming catalysts as key drivers of value.
